A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients
Figure 2
Estimated rate of patients free from recurrence of HCV Infection (Kaplan-Meier Method) at 12 months as confirmed by central biopsy. Freedom from HCV recurrence at 12 months was 19.1% with the TAC/DAC steroid-free protocol and 13.8% with the TAC/STR protocol (Kaplan-Meier method) with a significant difference in survival curves between treatments (95% CI, −0.105 to 0.211%; , Wilcoxon Gehan test). Protocol biopsies were performed at months 6 and 12 accounting for the higher number of events reported at these time points. TAC: tacrolimus; DAC: daclizumab; STR: steroids.
